MSc, Biotechnology, McGill University, Montreal, Canada
BSc, Genetics, University of Western Ontario, London, Canada

As a member of PDCI’s Pricing and Policy team, Dylan has lead dozens of strategic pricing assessments, leveraging his PMPRB expertise in assisting clients with business cases for pricing strategies for new launches and in-market patented medicines. Dylan is a trusted PMPRB Pricing expert to his many clients, providing strategic pricing plans, ensuring regulatory compliance, assessing and advising on “willingness-to-pay” in public and private markets, and leading clients’ negotiations through Voluntary Compliance Undertakings. Dylan has worked with many key industry stakeholders in estimating the impact of the 2020 PMPRB Regulatory reforms.

Working in the PDCI’s Data Innovation team, Dylan helps develop and maintain PDCI’s data analytics services including PDCI’s Market Access Toolkit, national public claims data, private claims data, and price trends. Dylan leverages this experience to assist with PDCI’s whitepaper publications on topics including National Pharmacare and the Impact of COVID-19 lockdowns on market access and reimbursement.

Prior to joining PDCI’s Pricing and Policy Team, Dylan developed health economic models (cost-utility, cost-effectiveness, and cost-consequence) and budget impact analysis (BIA) models for submission to Canadian HTA agencies (CADTH CDR & pCODR, INESSS) and private payers.

Dylan holds a Master’s degree in Applied Science from McGill University in Montreal, and a Bachelor’s degree in Science with and Honor’s Specialization in Genetics from University of Western Ontario in London Ontario.